RICARDO ROMITI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Generalized Lenticular Atrophoderma of Pasini and Pierini(2015) AVANCINI, Joao; VALENTE, Neusa Yuriko S.; ROMITI, RicardoWe present a 16-year-old boy with multiple, well-circumscribed, atrophic, light-brown patches on his neck, chest, and back. The authors believe that it represents an unusual presentation of atrophoderma of Pasini and Pierini and suggest the designation generalized lenticular APP.
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial(2015) BISSONNETTE, R.; IVERSEN, L.; SOFEN, H.; GRIFFITHS, C. E. M.; FOLEY, P.; ROMITI, R.; BACHINSKY, M.; ROTTINGHAUS, S. T.; TAN, H.; PROULX, J.; VALDEZ, H.; GUPTA, P.; MALLBRIS, L.; WOLK, R.Background Tofacitinib is an oral Janus kinase inhibitor being investigated for the treatment of moderate-to-severe plaque psoriasis. Objectives To compare outcomes following tofacitinib withdrawal with outcomes of continuation. Methods In this phase 3 study (NCT01186744), patients received tofacitinib 5 mg (n = 331) or 10 mg (n = 335) twice daily for 24 weeks. The patients who achieved both >= 75% reduction in Psoriasis Area and Severity Index (PASI 75) score from baseline and Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) received a placebo (withdrawal) or the previous dose. At relapse (> 50% reduction in the PASI improvement during initial treatment) or week 40, the patients received the initial dose. Results Initial treatment: 33.5% and 55.2% achieved both PASI 75 and PGA responses with tofacitinib 5 and 10 mg twice daily, respectively, making them eligible for the treatment-withdrawal period. Withdrawal: 56.2%, 62.3%, 23.3% and 26.1% maintained PASI 75 responses with tofacitinib 5, 10 mg, placebo (5 mg) and placebo (10 mg) twice daily, respectively; 49.9%, 63.9%, 22.9% and 18.0% maintained PGA responses; and 92.3%, 93.0%, 32.8% and 42.9% did not relapse. Elevations in low-density lipoprotein-cholesterol levels following initial treatment (mean increase: 8.71 mg dL(-1) with 5 mg twice daily, 10.26 mg dL(-1) with 10 mg twice daily) were reversed upon withdrawal. Retreatment: 36.8% and 61.0% of patients who relapsed achieved PASI 75 responses with tofacitinib 5 or 10 mg after 16 weeks; 44.8% and 57.1% regained PGA responses. Conclusions Patients who received continuous treatment maintained a response more effectively when compared with placebo recipients. Safety profiles were comparable in both the continuous treatment group and retreatment group. Of those patients who relapsed, up to 60% recaptured a response with tofacitinib.
- Pili Annulati and Trichorrhexis Nodosa in the Same Patient: Cause or Coincidence?(2015) DONATI, Aline; ANDRIOLO, Anna Cecilia; BARLETTA, Marina; VALENTE, Neusa; ROMITI, RicardoPurpose: To determine the relationship between pili annulati (PA) and acquired trichorrhexis nodosa (TN) seen in the same patient, considering the two main theories evoked by previous studies: greater stiffness of darker PA bands or associated cuticular damage. Procedures: Light microscopy of hair shafts from different regions of the patient's scalp. Results: TN was not superimposed to dark bands of PA. Conclusions: Greater stiffness of darker PA bands was excluded as the cause of hair breakage. Hair breakage in PA patients might be related to cuticular abnormalities, as previously reported. Because weathering of long thin chemically treated hairs is extremely common, coincidence cannot be completely ruled out in this case. (C) 2015 S. Karger AG, Basel
bookPart Manifestações dermatológicas na doença inflamatória intestinal(2015) ROMITI, Ricardo; CéSAR, Sabrina Sisto Alessi- Persistent eyelid edema and erythema as manifestation of lupus erythematosus: a series of six cases(2015) SILVA, Lana Luiza da Cruz; ROMITI, Ricardo; NICO, Marcello Menta Simonsen
- Localized scleroderma: clinical spectrum and therapeutic update(2015) CARETA, Mariana Figueiroa; ROMITI, RicardoScleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis and visceral involvement, and localized scleroderma or morphea which classically presents benign and self-limited evolution and is confined to the skin and/or underlying tissues. Localized scleroderma is a rare disease of unknown etiology. Recent studies show that the localized form may affect internal organs and have variable morbidity. Treatment should be started very early, before complications occur due to the high morbidity of localized scleroderma. In this review, we report the most important aspects and particularities in the treatment of patients diagnosed with localized scleroderma.
conferenceObject Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial(2015) BISSONNETTE, R.; IVERSEN, L.; SOFEN, H.; GRIFFITHS, C. E. M.; FOLEY, P.; ROMITI, R.; BACHINSKY, M.; ROTTINGHAUS, S. T.; TAN, H.; PROULX, J.; VALDEZ, H.; GUPTA, P.; MALLBRIS, L.; WOLK, R.- Prevalence of Psoriatic Arthritis in a Large Cohort of Brazilian Patients with Psoriasis(2015) RANZA, Roberto; CARNEIRO, Sueli; QURESHI, Abrar A.; MARTINS, Gladys; RODRIGUES, Jose Joaquim; ROMITI, Ricardo; BARROS, Thiago Bitar M.; CARNEIRO, Jamille; SAMPAIO, Ana Luisa; GRYNSZPAN, Rachel; MARKUS, Juliana; PINTO, Rogerio Melo Costa; GOLDENSTEIN-SCHAINBERG, ClaudiaObjective. To determine the prevalence of psoriatic arthritis (PsA) in a large cohort of Brazilian patients with psoriasis (PsO) being seen at dermatology centers. Methods. A multicenter study was conducted in 4 university dermatology clinics. In each center, consecutive patients with confirmed diagnoses of PsO were evaluated by a rheumatologist. Individuals were classified as having PsA according to the ClASsification criteria for Psoriatic ARthritis (CASPAR). Laboratory tests and radiographs were performed, as needed, based on the clinical judgment of the rheumatologist. Results. A total of 524 patients with PsO were evaluated. The mean age was 48.5 +/- 14.5 years, 50% were women, and the mean PsO duration was 15.4 +/- 11.7 years. A diagnosis of PsA was documented in 175 patients (33%), of whom 49% were newly identified by the rheumatologist. Most individuals with PsA (72%) had peripheral involvement, 11% had isolated axial involvement, and 17% had both peripheral and axial involvement. Dactylitis occurred in 20% and clinical enthesitis in 30% of the patients. Laboratory and/or radiograph tests were necessary for a definitive diagnosis of PsA in 42 of 175 individuals (24%). Conclusion. In our study, one-third of Brazilian patients with PsO, followed in dermatology settings, were diagnosed with PsA by a rheumatologist. Almost half of subjects with PsA had no previous diagnosis. A collaboration between dermatologists and rheumatologists is greatly needed to establish earlier PsA diagnoses and adequate multidisciplinary management.
bookPart Manifestações dermatológicas na doença inflamatória intestinal(2015) ROMITI, Ricardo; CéSAR, Sabrina Sisto Alessi